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ABSTRACT

L

eukemia stem cells (LSC) are more resistant to standard chemotherapy
and their persistence during remission can cause relapse, which is still
one of the major clinical challenges in the treatment of acute myeloid
leukemia (AML). A better understanding of the mutational patterns and the
prognostic impact of molecular markers associated with stemness could
lead to better clinical management and improve patients’ outcomes. We
applied a previously described 17-gene expression score comprising genes
differently expressed between LSC and leukemic bulk blasts, for 934 adult
patients with de novo AML, and studied associations of the 17-gene LSC
score with clinical data and mutation status of 81 genes recurrently mutated
in cancer and leukemia. We found that patients with a high 17-gene score
were older and had more mutations. The 17-gene score was found to have
a prognostic impact in both younger (aged <60 years) and older (aged ≥60
years) patients with AML. We also analyzed the 17-gene LSC score in the
context of the 2017 European LeukemiaNet genetic-risk classification and
found that for younger patients the score refined the classification, and
identified patients currently classified in the European LeukemiaNet
Favorable-risk category who had a worse outcome.
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease.1-3 Although many
advances have been made in understanding the biology and treatment of AML, the
long-term survival rates are still only ~40% for younger adults (aged <60 years),
and ~10-15% for older patients (aged ≥60 years).1-3 One major clinical challenge
impeding improved outcome is relapse following achievement of complete remission (CR). It is hypothesized that relapse occurs because of the persistence of
leukemia stem cells (LSC) and subsequent outgrowth of the leukemia clone.4-8
Studies on the clinical relevance of LSC are still rare because no LSC-specific phenotype has been firmly established. Although the percentage of CD34+/CD38-expressing cells, which were initially assumed to include all LSC, was shown to
affect prognosis,9,10 the use of more permissive immunodeficient mouse models
revealed that LSC can also be found in the CD34+/CD38+ and CD34- compartments.4,7,9,11-15 Instead of using surface markers to identify and quantify the presence
haematologica | 2020; 105(3)
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of LSC, in 2011, Eppert et al.4 described a LSC-related
gene-expression signature comprising 44 genes that were
deregulated in LSC. The derived stem cell-like signature
was shown to associate with inferior outcome in adult
patients with cytogenetically normal AML.4,16 Recently, Ng
et al.7 used a similar approach to generate a LSC-derived
gene-expression signature consisting of 17 genes that also
associated with inferior outcome. However, it is still not
fully determined whether this signature is associated with
clinical characteristics and gene mutations. Moreover, the
prognostic value of the 17-gene LSC score in the context
of other, well-established risk classifications, for example
the one by the European LeukemiaNet (ELN)1, has not, to
our knowledge, been assessed.
We, therefore, derived the 17-gene score from a set of
samples from adults with AML and determined associations between the signature and known prognosticators1,17,18 as well as mutational data of 81 cancer- and
leukemia-associated genes.19 Moreover, we validated the
prognostic impact of the 17-gene signature alone and in
the context of the 2017 ELN genetic-risk classification.1

Methods
Patients and treatment
We investigated 934 adult patients with de novo AML (other
than acute promyelocytic leukemia), for whom material for
molecular analyses was available. Availability of material for
analysis was the only criterion for inclusion in our study – we
did not select AML patients based on their age, ELN risk group,
specific clinical trial they were enrolled onto, etc. Because of
differences in the treatment protocols between younger and
older patients, we performed outcome analyses separately for
these two groups of patients. Within each age group, patients
were treated similarly, receiving a cytarabine/anthracyclinebased induction on Cancer and Leukemia Group B (CALGB) trials.20-34 No patient received an allogeneic stem cell transplant in
first CR. Details of CALGB treatment protocols are provided in
the Online Supplementary Appendix and Online Supplementary Table
S1. There were no significant differences in CR rates, disease-free
survival (DFS) or overall survival (OS) for younger patients
enrolled onto CALGB 8525, 9222, 9621, 10503, 10603 and 19808
treatment trials (Online Supplementary Table S2) nor were there
any significant differences in CR rates, DFS or OS among older
patients enrolled onto CALBG 9420, 9720, 10201 and 10502 trials
(Online Supplementary Table S3). CALGB is now part of the
Alliance for Clinical Trials in Oncology (Alliance). All patients
were enrolled on CALGB 8461 (cytogenetic studies), CALGB
9665 (leukemia tissue bank) and CALGB 20202 (molecular studies) companion protocols. Patients provided written informed
consent, and study protocols were in accordance with the
Declaration of Helsinki and approved by Institutional Review
Boards.

Transcriptome analyses and calculation of the 17-gene
leukemia stem cell score
Pretreatment bone marrow and/or blood samples containing
≥20% leukemic blasts were obtained from all patients and
mononuclear cells were enriched through Ficoll-Hypaque gradient centrifugation and cryopreserved until use. Total RNA was
extracted from patients’ samples using the TRIzol method
according to the manufacturer’s protocol and used for RNAsequencing analyses (see also the Online Supplementary
Appendix). RNA-sequencing libraries were prepared using the
722

Illumina (San Diego, CA, USA) TruSeq Stranded Total RNA
Sample Prep Kit with Ribo-Zero Gold (n. RS1222201) according
to the manufacturer's instructions. Sequencing was performed
with Illumina HiSeq systems using the HiSeq version 3 sequencing reagents to an approximate cluster density of 800,000/mm2.
Image analysis, base calling, error estimation, and quality
thresholds were performed using HiSeq Controller software
(version 2.2.38) and Real Time Analyzer software (version
1.18.64). Transcript abundance was quantified from the RNAsequencing data using kallisto,35 with a reference transcriptome
consisting of Homo sapiens GRCh38 protein-encoding and noncoding transcripts except rRNA; the strand-specific option of
“first read reverse” was chosen. Abundance values are represented in transcripts per million.
The 17-gene LSC score was derived similarly to that in the
publication by Ng et al.7 using RNA-sequencing data and the
same weights that were published initially for a microarray platform.7 Briefly, the 17-gene LSC score was calculated as the
weighted sum of the normalized expression values of the 17
genes included in the signature: 17-gene LSC score = (DNMT3B
× 0.0874) + (ZBTB46 × −0.0347) + (NYNRIN × 0.00865) +
(ARHGAP22 × −0.0138) + (LAPTM4B × 0.00582) + (MMRN1 ×
0.0258) + (DPYSL3 × 0.0284) + (KIAA0125 × 0.0196) + (CDK6 ×
−0.0704) + (CPXM1 × −0.0258) + (SOCS2 × 0.0271) + (SMIM24
× −0.0226) + (EMP1 × 0.0146) + (NGFRAP1 × 0.0465) + (CD34
× 0.0338) + (AKR1C3 × −0.0402) + (GPR56 × 0.0501).7 The
derived scores were used to divide patients into two groups
using the median as the cutoff: a group with a high score (17genehigh) and a group with a low score (17-genelow).

Cytogenetic and molecular analyses
Details of the cytogenetic and molecular analyses are provided
in the Online Supplementary Appendix.

Results
Clinical and cytogenetic characteristics associated
with the 17-gene leukemia stem cell score
Pretreatment characteristics of the 934 patients are
shown in Table 1. For all patients, we determined the 17gene LSC score, which indicates a stem cell-like geneexpression profile, and separated them into 17-genelow and
17-genehigh groups using the median. Comparison between
patients with a 17-genelow and 17-genehigh score showed
that the former were younger at diagnosis (median: 46 vs.
53 years; P<0.001) and had lower platelet counts (median:
50 vs. 63x109/L; P<0.001). Cytogenetically, there was no
difference in the frequency of the presence of cytogenetically normal AML between the groups. Among cytogenetically abnormal patients, those with a 17-genelow score
more frequently had core-binding factor AML (CBF-AML;
P<0.001), including all patients with t(8;21)(q22;q22) and
88% with inv(16)(p13q22) or t(16;16)(p13;q22). On the
other hand, the group with a 17-genehigh score included all
patients with inv(3)(q21q26) or t(3;3)(q21;q26) and contained more patients with a complex karyotype than in
the 17-genelow group (P<0.001). Most patients with a complex karyotype in the 17-genehigh group had a typical complex karyotype (i.e., complex karyotype with unbalanced
chromosome abnormalities leading to loss of material
from 5q, 7q and/or 17p), whereas an atypical complex
karyotype (i.e., complex karyotype without 5q, 7q and/or
17p abnormalities)36 was found with a higher frequency
among 17-genelow patients.
haematologica | 2020; 105(3)
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Table 1. Comparison of pretreatment clinical and cytogenetic characteristics
in 934 patients with acute myeloid leukemia according to low and high 17gene leukemia stem cell scores.

Characteristic

All patients
(n=934)

Age, years
Median
50
Range
17-84
Sex, n (%)
Female
404 (43)
Hemoglobin, g/dL
Median
9.2
Range
2.3-25.1
Platelet count, x109/L
Median
55
Range
4-592
WBC count, x109/L
Median
24.1
Range
0.4-475.0
% Blood blasts
Median
54
Range
0-99
% Bone marrow blasts
Median
65
Range
0-97
EM involvement, n (%)
Present
220 (25)
FAB classification, n (%)
M0
40 (6)
M1
150 (22)
M2
185 (27)
M4
189 (28)
M5
113 (17)
M6
1 (0)
M7
1 (0)
ELN group, n (%)
Favorable
385 (45)
t(8;21)
40
inv(16)
69
NPM1 mut/FLT3-ITD wt or low 211
CEBPA mut
65
Intermediate
188 (22)
Adverse
291 (34)
Cytogenetically normal, n (%)
Present
442 (47)
CBF, n (%)
Present
109 (12)
t(8;21)
40
inv(16)
69
KMT2A-rearranged, n (%)
Present
46 (5)
t(9;11)
19
t(v;11)
27
Complex karyotype, n (%)
Present
79 (8)
Typical
53
Atypical
26
t(6;9), n (%)
Present
5 (1)
inv(3), n (%)
Present
18 (2)

17-genelow
(n=467)

17-genehigh
(n=467)

P

46
17-82

53
17-84

<0.001

199 (43)

205 (44)

0.74

9.2
2.3-25.1

9.1
4.2-14.7

0.31

50
7-433

63
4-592

<0.001

24.1
0.4-303.6

23.9
0.6-475

0.46

54
0-97

54
0-99

0.18

65
0-97

66
4-97

0.91

112 (25)

108 (24)

0.88
0.18

16 (4)
82 (23)
100 (28)
107 (30)
52 (15)
0 (0)
0 (0)

24 (7)
68 (21)
85 (26)
82 (25)
61 (19)
1 (1)
1 (1)

284 (64)
40
61
123
60
69 (16)
89 (20)

101 (24)
0
8
88
5
119 (28)
202 (48)

210 (45)

232 (50)

101 (22)
40
61

8 (2)
0
8

21 (5)
9
12

25 (5)
10
15

19 (4)
4
15

60 (13)
49
11

2 (1)

3 (1)

0

18 (4)

To obtain more detailed insights into the mutational
patterns associated with the 17-gene LSC signature, we
analyzed 81 cancer and leukemia-associated genes.19 We
found that 77 genes were mutated in at least one patient
(Online Supplementary Table S4). Patients with a 17-genelow
score had fewer mutations compared with patients with
a 17-genehigh score (median: 2 vs. 3; P<0.001). Moreover,
12 gene mutations occurred at significantly different frequencies between patients with 17-genelow and 17-genehigh
scores (Figure 1). Biallelic CEBPA (P<0.001), GATA2
(P=0.008), and KIT (P<0.001) mutations were more frequent in the 17-genelow group of patients (Figure 1A). In
contrast, patients with a 17-genehigh score more frequently
harbored mutations in ASXL1 (P=0.001), DNMT3A
(P<0.001), KMT2A (P=0.04), RUNX1 (P=0.002), SRSF2
(P=0.02), STAG2 (P=0.009), TET2 (P=0.008) and TP53
(P<0.001) genes. Additionally, FLT3-internal tandem
duplications were more frequent in these patients than in

A

<0.001

B
0.17
<0.001

0.65

<0.001

1.00
<0.001

WBC: white blood cell; EM: extramedullary; FAB: French-American-British; ELN: European
LeukemiaNet; mut: mutated; ITD: internal tandem duplication; wt: wild-type; CBF: core-binding
factor.
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Mutational landscape associated with the 17-gene
leukemia stem cell score

Figure 1. Differences in the frequencies of gene mutations between patients
with low and those with high 17-gene leukemic stem cell scores. Mutations
that had a significantly higher frequency in the (A) 17-genelow or (B) 17-genehigh
group.
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those with a 17-genelow score (P<0.001) (Figure 1B and
Online Supplementary Table S4), as previously described by
Ng et al.7

Outcome associated with the 17-gene leukemia
stem cell score
All patients were assigned to the 17-genelow and 17-genehigh
groups based on the median of the initial analysis of the
entire cohort of patients. We kept this initial grouping for
all additional sub-analyses that could have potentially reassigned some patients into different 17-gene score

groups. This led to differences in the sizes of the 17-genelow
and 17-genehigh score groups in younger and older patients.
Similarly to Ng et al.,7 we found that the 17-gene LSC
score was strongly associated with outcome in both the
younger (Table 2; Figure 2A, B) and older (Table 2; Figure
2C, D) cohorts of patients. Among younger patients, those
with a 17-genelow score had higher CR rates (P<0.001)
(Table 2) and longer DFS (P<0.001) (Figure 2A) and OS
(P<0.001) (Figure 2B). Similar results were found in older
patients: CR rates (P=0.004) (Table 2), DFS (P=0.04),
(Figure 2C) and OS (P<0.001) (Figure 2D).

Table 2. Comparison of outcomes according to the 17-gene leukemic stem cell score in younger adults (aged <60 years) and older adults (aged
≥60 years) with acute myeloid leukemia.

Endpoint
Complete remission, %
Disease-free survival
Median, years
% disease-free at 3 years
95% confidence interval
Overall survival
Median, years
% alive at 3 years
95% confidence interval

Endpoint
Complete remission, %
Disease-free survival
Median, years
% disease-free at 3 years
95% confidence interval
Overall survival
Median, years
% alive at 3 years
95% confidence interval

Endpoint
Complete remission,%
Disease-free survival
Median, years
% disease-free at 3 years
95% confidence interval
Overall survival
Median, years
% alive at 3 years
95% confidence interval

Endpoint
Complete remission, %
Disease-free survival
Median, years
% disease-free at 3 years
95% confidence interval
Overall survival
Median, years
% alive at 3 years
95% confidence interval

Younger patients
(n=729)
17-genelow (n=403) 17-genehigh (n=326)
87

63

2.6
48
43-53

0.7
26
20-32

6.5
59
54-63

1.1
27
22-321

P

17-genelow (n=64)

Older patients
(n=205)
17-genehigh (n=141)

<0.001
<0.001

72

50

0.6
17
8-30

0.5
6
2-13

1.1
27
16-38

0.6
9
5-14

<0.001

17-genelow (n=264)

81

7.7
57
50-63

1.4
43
31-55

NR
68
62-73

2.4
49
37-59

<0.001
0.008

17-genehigh (n=23)

P

90

78

0.42
0.09

1.1
39
17-60

0.6
17
4-37

2.4
50
27-69

1.1
17
5-35

<0.001

17-genelow (n=56)

0.05

ELN Intermediate-risk group
17-genehigh (n=96)
P
17-genelow (n=13)

82

76

1.3
28
16-42

0.7
25
15-35

2.4
45
31-57

1.4
28
20-37

0.42
0.08

17-genehigh (n=23)

P

62

43

0.49
0.92

0.7
0

0.4
10
1-36

0.9
0

0.7
17
5-35

0.03

17-genelow (n=67)

0.48

ELN Adverse-risk group
17-genehigh (n=123)
P
17-genelow (n=22)

63

41

1.1
24
12-37

0.6
6
2-15

1.6
40
29-52

0.7
11
7-18

0.004
<0.001

0.004
0.04

<0.001

ELN Favorable-risk group
17-genehigh (n=78)
P
17-genelow (n=20)

95

P

17-genehigh (n=79)

P

59

41

0.15
0.21

0.5
8
0-29

0.4
0

0.8
18
6-36

0.5
4
1-10

<0.001

0.06

NR: not reached.
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Adverse-risk group (41%), followed by the Intermediate(32%) and Favorable-risk (26%) groups. Among the older
patients, the majority in both the 17-genelow and 17-genehigh
score groups were classified in the Adverse-risk group
(40% and 63%, respectively) (Online Supplementary Table
S5), followed by Favorable- (36%) and Intermediate(24%) risk groups in the 17-genelow group and by equal
numbers for Favorable-risk (18%) and Intermediate-risk
(18%) groups in the 17-genehigh group.
Next, we tested whether the 17-gene LSC score can be
used to refine the prognostic impact of the ELN classification. Among younger patients, we found that the 17-gene
LSC score could refine the ELN classification for the ELN
Favorable- and Adverse-risk groups, but not for the
Intermediate-risk group. Younger patients with a 17genelow score in the ELN Favorable-risk group had higher
CR rates (P<0.001) (Table 2) and longer DFS (P=0.008)
(Figure 3A) and OS (P<0.001) (Figure 3B) than the 17genehigh patients. Likewise, younger Adverse-risk patients
with a 17-genelow score had higher CR rates (P=0.004)
(Table 2), and longer DFS (P<0.001) (Figure 3E) and OS
(P<0.001) (Figure 3F). On the other hand, among younger
patients in the Intermediate-risk group, there was no significant difference in CR rates (Table 2) or DFS (P=0.08)

Next, we tested the prognostic impact of the 17-gene
LSC score in multivariable analyses (Table 3). In younger
patients, the 17-gene LSC score remained prognostically
significant for all clinical endpoints, namely CR, DFS, and
OS. In older patients, the score was prognostically significant only for OS, but it was not significant in the final
models for achievement of a CR or DFS (Table 3).

Prognostic impact of the 17-gene leukemia stem cell
score in the context of the current European
LeukemiaNet classification
To test the prognostic value of the 17-gene LSC score in
the context of the current 2017 ELN classification, we classified all patients according to the published guidelines
into ELN Favorable-, Intermediate- and Adverse-risk
groups.1 In both age cohorts, we found significant differences in the ELN risk-group distribution between patients
with 17-genelow and 17-genehigh scores (P<0.001 for younger
and P=0.009 for older patients). Among the younger
patients, two-thirds with a 17-genelow score were classified
as having Favorable-risk, whereas 14% and 17% were
classified as having, respectively, Intermediate- and
Adverse-risk. On the other hand, younger patients with a
17-genehigh score were most frequently classified in the

A

B

C

D

Figure 2. Differences in outcome between patients with low and those with high 17-gene leukemic stem cell scores. (A) Disease-free survival (DFS) and (B) overall
survival (OS) of younger adult patients (aged <60 years) according to the 17-gene leukemia stem cell (LSC) score. (C) DFS and (D) OS of older patients (aged ≥60
years) according to the 17-gene LSC score.

haematologica | 2020; 105(3)
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(Figure 3C), but those with a 17-genelow score had longer
OS (P=0.03) (Figure 3D).
Among older patients, the 17-gene score had almost no
impact on outcome after classifying the patients according
to the ELN recommendations. We found that only older
patients in the Favorable-risk group with a 17-genelow score
had longer OS than those with a 17-genehigh score (P=0.05)
(Online Supplementary Figure S1, Table 2). The 17-gene
score showed no prognostic impact in the Adverse- and
Intermediate-risk groups.

Discussion
The prognosis of AML patients is still poor, and relapse
after achieving a CR is a major clinical challenge.1-4,7 It is
thought that leukemia relapse is caused by the persistence
of LSC.4-7 A better understanding of LSC and their prognostic impact in AML is necessary in order to improve
patients’ outcomes. However, the lack of a well-established phenotype has thus far impeded studies on the clinical relevance of LSC frequency. Ng et al.7 recently developed a gene-expression signature, consisting of 17 genes
that were found to be deregulated in LSC, to quantify the
presence of LSC. They showed that the 17-gene LSC sig-

nature has a prognostic impact. In our study, we not only
validated these data in an independent set of 934 adult
patients with de novo AML, but also analyzed the prognostic impact of the 17-gene LSC score in the context of the
current ELN classification. Moreover, we describe a
detailed mutational landscape associated with the 17-gene
LSC score.
Whereas the 17-gene score was initially derived using
microarray data, Ng et al.7 showed in a relatively small set
of patients (n=169) that RNA-sequencing data can also be
used to derive the score. We validated this finding in a
larger set of 934 AML patients with RNA-sequencing data
using the same published weights of the score as Ng et al.,7
and demonstrated the robustness of the 17-gene score. We
assigned the score to each patient and classified them into
a 17-genehigh or 17-genelow LSC group for all further analyses, using the median as the cut point.
Clinically, we found that patients with a 17-genelow score
were younger and had lower platelet counts at diagnosis.
Similar differences in age were also described by Ng et al.7
Next, we compared cytogenetic findings between the
groups of patients with 17-genelow and 17-genehigh scores
and although we did not find any difference in the incidence of cytogenetically normal AML, there was a different distribution of the specific cytogenetic abnormalities

Table 3. Multivariable models for outcome evaluating the 17-gene leukemia stem cell score and known prognosticators in younger (aged <60
years) and older (aged ≥60 years) adults with acute myeloid leukemia.

End point

Variable

Complete
remission

17-gene LSC score (high vs. low)
ELN 2017
(Intermediate vs. Favorable),
(Adverse vs. Favorable)
WT1 (mutated vs. wild-type)
ZRSR2 (mutated vs. wild-type)
BAALC expression (high vs. low)
Hemoglobin (continuous)

Disease-free
survival

Overall
survival

17-gene LSC score (high vs. low)
ELN 2017
(Intermediate vs. Favorable,
Adverse vs. Favorable)
DNMT3A (mutated vs. wild-type)
WT1 (mutated vs. wild-type)
Platelets (continuous, 50-unit increase)
17-gene LSC score (high vs. low)
ELN 2017
(Intermediate vs. Favorable),
(Adverse vs. Favorable)
WT1 (mutated vs. wild-type)
Age (continuous, 10-year increase)
BAALC expression (high vs. low)
Platelets (continuous, 50-unit increase)

Younger patients
(n=729)
Odds ratio
P
(95% CI)
0.36 (0.23-0.56)
0.48 (0.26-0.86)
0.12 (0.07-0.21)
0.47 (0.24-0.92)
0.44 (0.19-0.99)
0.60 (0.39-0.92)
1.16 (1.03-1.30)

<0.001
<0.001

Older patients
(n=205)
Odds ratio
P
(95% CI)
*

*

0.03
0.05
0.02
0.01

Hazard ratio
(95% CI)

P

Hazard ratio
(95% CI)

P

1.67 (1.31-2.13)

<0.001
<0.001

*

*

1.70 (1.19-2.41)

0.003

1.71 (1.23-2.38)
0.86 (0.77-0.96)

0.001
0.007

1.84 (1.39-2.42)
2.87 (2.16-3.81)
1.41 (1.09-1.82)
1.94 (1.34-2.80)
0.87 (0.80-0.95)
1.88 (1.53-2.31)
1.77 (1.37-2.29)
2.85 (2.26-3.60)
1.80 (1.33-2.44)
1.17 (1.07-1.27)

0.008
<0.001
0.003
<0.001
<0.001
<0.001
<0.001

95% CI: 95% confidence interval; ELN: European LeukemiaNet. An odds ratio >1 (<1) corresponds to a higher (lower) odds of achieving a complete remission for higher values
of continuous variables and the first level listed of a dichotomous variable. A hazard ratio >1 (<1) corresponds to a higher (lower) risk for higher values of continuous variables
and the first level listed of a dichotomous variable.Variables were considered for inclusion in the multivariable models if they had a univariable P-value of <0.20. Only markers
for which there were at least eight mutated patients in each 17-gene score group (high/low) were included the multivariable modeling. * the 17-gene score does not remain statistically significant in the multivariable model for achievement of a complete remission and disease-free survival in older patients. .
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abnormalities associated with adverse outcome, such as a
complex karyotype, especially a typical complex karyotype,36 and inv(3)(q21q26) or t(3;3)(q21;q26).1,17,36,40-42 Of
note, patients with inv(3) or t(3;3) were classified exclusively in the 17-genehigh score group.
Next, we looked for differences in the mutational patterns of 81 cancer- and leukemia-associated genes19
between 17-genelow and 17-genehigh score patients. Patients

between the groups. Patients with CBF-AML were much
more frequently classified in the 17-genelow score group,
especially those with a t(8;21)(q22;q22) who were never
found to have a 17-genehigh score. As previously reported,
patients with CBF-AML had a relatively favorable outcome compared with patients belonging to other cytogenetic subgroups.37-41 On the other hand, patients in the 17genehigh score group more frequently carried cytogenetic

A

B

C

D

E

F

Figure 3. Differences in outcome between younger adult patients (aged <60 years) with low and those with high 17-gene leukemic stem cell scores in the context
of the current European LeukemiaNet 2017 classification. (A) Disease-free survival (DFS) and (B) overall survival (OS) of younger patients within the European
LeukemiaNet (ELN) Favorable-risk group according to the 17-gene leukemia stem cell (LSC) score. (C) DFS and (D) OS of younger patients within the ELN
Intermediate-risk group according to the 17-gene LSC score. (E) DFS and (F) OS of younger patients within the ELN Adverse-risk group according to the 17-gene LSC
score.
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with a 17-genelow score had a lower median number of
mutations and only three genes, namely, GATA2, CEBPA
and KIT, were found to be mutated more frequently in
this group. GATA2 mutations and biallelic CEBPA mutations are known to co-occur,43 and the higher incidence of
KIT mutations in 17-genelow patients can be at least in part
explained by the elevated frequency of CBF-AML in this
group, since KIT mutations are associated with CBFAML.37 Whereas both biallelic CEBPA mutations and
GATA2 mutations, which occurred frequently in the 17genelow score group, are associated with a favorable outcome, mutations associated with adverse outcome, such
as those in the RUNX1, ASXL1, and TP53 genes,1,2,36,44-50
were more frequently found in patients with a 17-genehigh
score.
We were also interested in characterizing further the
prognostic significance of the 17-gene LSC score established by Ng et al.7 We not only validated its prognostic
impact in a larger independent cohort of patients, but also
asked the question whether the 17-gene LSC score could
refine the well-established 2017 ELN classification.1 This is
especially of interest because it appears that some patients
classified as ELN Favorable-risk still have a poor outcome.
These patients might benefit from other treatment
options.1 When we classified the patients according to the
ELN guidelines, we found significant differences in the
distribution of patients with 17-genelow and 17-genehigh
scores among specific ELN risk groups. In younger
patients, the majority of 17-genelow score patients were
classified as having Favorable-risk, whereas most patients
in the 17-genehigh score group were in the Adverse-risk
group.
With regard to clinical outcome, we found that the 17gene LSC score is capable of refining the ELN classification
in younger patients. In the Favorable-risk group, application of the 17-gene LSC score led to the identification of
approximately 20% of patients with a 17-genehigh score
who had a worse outcome than patients with a 17-genelow
score. Prospective studies are needed to test whether these
17-genehigh score patients might benefit from different
induction. A similar ability of the 17-gene LSC score to
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